Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jae Keith Joung
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Beacon Genomics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Beacon Genomics is focused on technologies for defining the safety and specificity of CRISPR-Cas9 nucleases and other genome editing technologies. This research project involves the use and development of genome editing technology and the research results from this project could affect the value of the company’s technology. The Partners HealthCare Committee on Outside Activities (COA) Financial Interest Review Panel evaluated Dr. Joung’s financial interest and determined that, based on the close connection between the interests of the company and this research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
Rare Sequence Variation and Diabetes Quantitative Traits
We aim to identify type 2 diabetes-quantitative trait (T2D-QT)-associated functional rare variants using WGS scans in ~3,700 white and black individuals from three cohorts in the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) consortium. We will phenotype T2D-QT rare variants with existing physiological data in CHARGE, including tests for T2D risk, annotate variants using ENCODE and other resources, and confirm predicted allele-specific molecular function in vitro with appropriate experiments in appropriate cells. T2D is a growing scourge worldwide. Innovative approaches are needed to identify new molecular targets for prevention and care. Genome-wide association studies for T2D and related quantitative traits like fasting glucose have dramatically advanced molecular understanding of glycemic regulation, but the causal variant and the functional basis of associations are unclear at many loci. We propose to move T2D genetics from common variant GWAS to rare variant WGS with deep annotation and in vitro validation to generate new molecular hypotheses that advance translation of genetics into better T2D prevention and care.
Filed on June 21, 2017.
Tell us what you know about Jae Keith Joung's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Jae Keith Joung”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Beam Therapeutics | Value cannot be readily determined |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Editas Medicine | >$600,000 |
| Jae Keith Joung | Dana Farber Cancer Inst | Conflict of Interest | Pairwise Plants | Value cannot be readily determined |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Editas Medicine | $10,000 - $19,999 |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Transposagen Biopharmaceuticals | Value cannot be readily determined |
| Jae Keith Joung | Dana Farber Cancer Inst | Conflict of Interest | Hera Testing Laboratories | Value cannot be readily determined |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Beam Therapeutics | Value cannot be readily determined |
| Jae Keith Joung | Dana Farber Cancer Inst | Conflict of Interest | Beam Therapeutics | Value cannot be readily determined |
| Jae Keith Joung | Massachusetts General Hospital | Conflict of Interest | Poseida Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.